Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.
We previously reported that synthetic vaccine particles (SVP) encapsulating antigens and TLR agonists resulted in augmentation of immune responses with minimal production of systemic inflammatory cytokines. Here we evaluated two different polymer formulations of SVP-encapsulated antigens and tested...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5983463?pdf=render |
id |
doaj-9f01f61eeda54a439de2914fa8f41d1c |
---|---|
record_format |
Article |
spelling |
doaj-9f01f61eeda54a439de2914fa8f41d1c2020-11-24T23:51:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019769410.1371/journal.pone.0197694Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.Petr O IlyinskiiGrigoriy I KovalevConlin P O'NeilChristopher J RoyAlicia M MichaudNatalia M DrefsMikhail A PechenkinFen-Ni FuLloyd P M JohnstonDmitry A OvchinnikovTakashi Kei KishimotoWe previously reported that synthetic vaccine particles (SVP) encapsulating antigens and TLR agonists resulted in augmentation of immune responses with minimal production of systemic inflammatory cytokines. Here we evaluated two different polymer formulations of SVP-encapsulated antigens and tested their ability to induce cytolytic T lymphocytes (CTL) in combination with SVP-encapsulated adjuvants. One formulation led to efficient antigen processing and cross-presentation, rapid and sustained CTL activity, and expansion of CD8+ T cell effector memory cells locally and centrally, which persisted for at least 1-2 years after a single immunization. SVP therapeutic dosing resulted in suppression of tumor growth and a substantial delay in mortality in several syngeneic mouse cancer models. Treatment with checkpoint inhibitors and/or cytotoxic drugs, while suboptimal on their own, showed considerable synergy with SVP immunization. SVP encapsulation of endosomal TLR agonists provided superior CTL induction, therapeutic benefit and/or improved safety profile compared to free adjuvants. SVP vaccines encapsulating mutated HPV-16 E7 and E6/E7 recombinant proteins led to induction of broad CTL activity and strong inhibition of TC-1 tumor growth, even when administered therapeutically 13-14 days after tumor inoculation in animals bearing palpable tumors. A pilot study in non-human primates showed that SVP-encapsulated E7/E6 adjuvanted with SVP-encapsulated poly(I:C) led to robust induction of antigen-specific T and B cell responses.http://europepmc.org/articles/PMC5983463?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Petr O Ilyinskii Grigoriy I Kovalev Conlin P O'Neil Christopher J Roy Alicia M Michaud Natalia M Drefs Mikhail A Pechenkin Fen-Ni Fu Lloyd P M Johnston Dmitry A Ovchinnikov Takashi Kei Kishimoto |
spellingShingle |
Petr O Ilyinskii Grigoriy I Kovalev Conlin P O'Neil Christopher J Roy Alicia M Michaud Natalia M Drefs Mikhail A Pechenkin Fen-Ni Fu Lloyd P M Johnston Dmitry A Ovchinnikov Takashi Kei Kishimoto Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. PLoS ONE |
author_facet |
Petr O Ilyinskii Grigoriy I Kovalev Conlin P O'Neil Christopher J Roy Alicia M Michaud Natalia M Drefs Mikhail A Pechenkin Fen-Ni Fu Lloyd P M Johnston Dmitry A Ovchinnikov Takashi Kei Kishimoto |
author_sort |
Petr O Ilyinskii |
title |
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. |
title_short |
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. |
title_full |
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. |
title_fullStr |
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. |
title_full_unstemmed |
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. |
title_sort |
synthetic vaccine particles for durable cytolytic t lymphocyte responses and anti-tumor immunotherapy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
We previously reported that synthetic vaccine particles (SVP) encapsulating antigens and TLR agonists resulted in augmentation of immune responses with minimal production of systemic inflammatory cytokines. Here we evaluated two different polymer formulations of SVP-encapsulated antigens and tested their ability to induce cytolytic T lymphocytes (CTL) in combination with SVP-encapsulated adjuvants. One formulation led to efficient antigen processing and cross-presentation, rapid and sustained CTL activity, and expansion of CD8+ T cell effector memory cells locally and centrally, which persisted for at least 1-2 years after a single immunization. SVP therapeutic dosing resulted in suppression of tumor growth and a substantial delay in mortality in several syngeneic mouse cancer models. Treatment with checkpoint inhibitors and/or cytotoxic drugs, while suboptimal on their own, showed considerable synergy with SVP immunization. SVP encapsulation of endosomal TLR agonists provided superior CTL induction, therapeutic benefit and/or improved safety profile compared to free adjuvants. SVP vaccines encapsulating mutated HPV-16 E7 and E6/E7 recombinant proteins led to induction of broad CTL activity and strong inhibition of TC-1 tumor growth, even when administered therapeutically 13-14 days after tumor inoculation in animals bearing palpable tumors. A pilot study in non-human primates showed that SVP-encapsulated E7/E6 adjuvanted with SVP-encapsulated poly(I:C) led to robust induction of antigen-specific T and B cell responses. |
url |
http://europepmc.org/articles/PMC5983463?pdf=render |
work_keys_str_mv |
AT petroilyinskii syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT grigoriyikovalev syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT conlinponeil syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT christopherjroy syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT aliciammichaud syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT nataliamdrefs syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT mikhailapechenkin syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT fennifu syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT lloydpmjohnston syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT dmitryaovchinnikov syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy AT takashikeikishimoto syntheticvaccineparticlesfordurablecytolytictlymphocyteresponsesandantitumorimmunotherapy |
_version_ |
1725475549249273856 |